| Not Yet Recruiting | MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma NCT06557330 | Fox Chase Cancer Center | Phase 2 |
| Recruiting | Studying TAK-243 in Patients With Advanced Cancer NCT06223542 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma NCT05783596 | Reid Merryman, MD | Phase 2 |
| Recruiting | The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia NCT05876923 | Mayo Clinic | N/A |
| Terminated | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies NCT05336409 | Century Therapeutics, Inc. | Phase 1 |
| Terminated | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL NCT05265975 | Antengene Corporation | Phase 1 / Phase 2 |
| Recruiting | Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent NCT04883437 | Emory University | Phase 2 |
| Recruiting | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapse NCT04223765 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers NCT04464200 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Withdrawn | Testing the Safety of CB-5339 in Patients With Cancer NCT04372641 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Ly NCT04323956 | Mayo Clinic | Phase 1 |
| Completed | IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma NCT04298879 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Completed | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma NCT04136756 | Nektar Therapeutics | Phase 1 |
| Completed | A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgk NCT04038359 | SecuraBio | Phase 2 |
| Active Not Recruiting | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgki NCT03884998 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lympho NCT03749018 | David Bond, MD | Phase 2 |
| Active Not Recruiting | Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas NCT03198026 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immun NCT03492775 | Prof. Dr. Wolfgang Hiddemann | Phase 2 |
| Completed | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma NCT03035331 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma NCT03105336 | Kite, A Gilead Company | Phase 2 |
| Terminated | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk NCT02483000 | Fred Hutchinson Cancer Center | Phase 1 |
| Unknown | Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma NCT02689869 | Ludwig-Maximilians - University of Munich | Phase 2 |
| Completed | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients Wi NCT02566304 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies NCT02362035 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Completed | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relap NCT02242045 | Gilead Sciences | Phase 1 |
| Completed | A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma NCT01882803 | SecuraBio | Phase 2 |
| Terminated | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Le NCT01944943 | The Lymphoma Academic Research Organisation | Phase 2 |
| Completed | Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Ma NCT01410513 | Sanofi | Phase 1 |
| Completed | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated NCT01231412 | Fred Hutchinson Cancer Center | Phase 3 |
| Unknown | Lenalidomide Plus Rituximab (R) in Non Follicular NHL NCT01830478 | Gruppo Italiano Studio Linfomi | Phase 2 |
| Completed | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treatin NCT00075478 | Fred Hutchinson Cancer Center | Phase 3 |